CR20210519A - Compuestos y métodos para reducir la expresión de kcnt1 - Google Patents
Compuestos y métodos para reducir la expresión de kcnt1Info
- Publication number
- CR20210519A CR20210519A CR20210519A CR20210519A CR20210519A CR 20210519 A CR20210519 A CR 20210519A CR 20210519 A CR20210519 A CR 20210519A CR 20210519 A CR20210519 A CR 20210519A CR 20210519 A CR20210519 A CR 20210519A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- methods
- kcnt1
- reducing
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819344P | 2019-03-15 | 2019-03-15 | |
| US201962884501P | 2019-08-08 | 2019-08-08 | |
| PCT/US2020/022680 WO2020190740A1 (en) | 2019-03-15 | 2020-03-13 | Compounds and methods for reducing kcnt1 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210519A true CR20210519A (es) | 2021-11-24 |
Family
ID=72520445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210519A CR20210519A (es) | 2019-03-15 | 2020-03-13 | Compuestos y métodos para reducir la expresión de kcnt1 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20220177893A1 (https=) |
| EP (1) | EP3938514A4 (https=) |
| JP (2) | JP7564817B2 (https=) |
| KR (1) | KR20210141983A (https=) |
| CN (3) | CN121674396A (https=) |
| AU (1) | AU2020241693B2 (https=) |
| BR (1) | BR112021015494A2 (https=) |
| CA (1) | CA3133247A1 (https=) |
| CL (1) | CL2021002398A1 (https=) |
| CO (1) | CO2021013371A2 (https=) |
| CR (1) | CR20210519A (https=) |
| IL (1) | IL285546A (https=) |
| JO (1) | JOP20210254A1 (https=) |
| MX (1) | MX2021011132A (https=) |
| PE (1) | PE20220168A1 (https=) |
| PH (1) | PH12021552220A1 (https=) |
| SG (1) | SG11202108625WA (https=) |
| TW (1) | TW202102675A (https=) |
| WO (1) | WO2020190740A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| MX2024006709A (es) * | 2021-12-01 | 2024-08-19 | Atalanta Therapeutics Inc | Composiciones y metodos para el tratamiento de epilepsias. |
| WO2025036916A1 (en) * | 2023-08-16 | 2025-02-20 | Les Laboratoires Servier | Oligonucleotides for modulating kcnt1 expression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
| US7601501B2 (en) * | 2006-08-11 | 2009-10-13 | The Scripps Research Institute | Controlling osteogenesis by inhibition of osteogenic suppressors |
| EP3260540A1 (en) * | 2010-11-12 | 2017-12-27 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| US20200129538A1 (en) | 2017-06-13 | 2020-04-30 | The Florey Institute Of Neuroscience And Mental Health | Compositions and methods for treating conditions associated with gain-of-function mutations in kcnt1 |
-
2020
- 2020-03-13 PE PE2021001518A patent/PE20220168A1/es unknown
- 2020-03-13 CR CR20210519A patent/CR20210519A/es unknown
- 2020-03-13 CN CN202511762645.3A patent/CN121674396A/zh active Pending
- 2020-03-13 CN CN202080020884.0A patent/CN113661241A/zh active Pending
- 2020-03-13 CA CA3133247A patent/CA3133247A1/en active Pending
- 2020-03-13 EP EP20773689.3A patent/EP3938514A4/en active Pending
- 2020-03-13 KR KR1020217032716A patent/KR20210141983A/ko not_active Withdrawn
- 2020-03-13 CN CN202311150264.0A patent/CN117106778A/zh active Pending
- 2020-03-13 MX MX2021011132A patent/MX2021011132A/es unknown
- 2020-03-13 WO PCT/US2020/022680 patent/WO2020190740A1/en not_active Ceased
- 2020-03-13 AU AU2020241693A patent/AU2020241693B2/en not_active Ceased
- 2020-03-13 BR BR112021015494-9A patent/BR112021015494A2/pt unknown
- 2020-03-13 JP JP2021555448A patent/JP7564817B2/ja active Active
- 2020-03-13 SG SG11202108625WA patent/SG11202108625WA/en unknown
- 2020-03-13 PH PH1/2021/552220A patent/PH12021552220A1/en unknown
- 2020-03-13 US US17/437,507 patent/US20220177893A1/en not_active Abandoned
- 2020-03-16 TW TW109108639A patent/TW202102675A/zh unknown
-
2021
- 2021-08-11 IL IL285546A patent/IL285546A/en unknown
- 2021-09-14 JO JOP/2021/0254A patent/JOP20210254A1/ar unknown
- 2021-09-14 CL CL2021002398A patent/CL2021002398A1/es unknown
- 2021-10-06 CO CONC2021/0013371A patent/CO2021013371A2/es unknown
-
2024
- 2024-09-27 JP JP2024168231A patent/JP2025000805A/ja active Pending
-
2025
- 2025-06-27 US US19/252,993 patent/US20250320505A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021002398A1 (es) | 2022-06-03 |
| MX2021011132A (es) | 2021-10-14 |
| PH12021552220A1 (en) | 2022-05-30 |
| WO2020190740A1 (en) | 2020-09-24 |
| EP3938514A4 (en) | 2023-05-03 |
| CA3133247A1 (en) | 2020-09-24 |
| IL285546A (en) | 2021-09-30 |
| EP3938514A1 (en) | 2022-01-19 |
| CN113661241A (zh) | 2021-11-16 |
| KR20210141983A (ko) | 2021-11-23 |
| US20250320505A1 (en) | 2025-10-16 |
| CN121674396A (zh) | 2026-03-17 |
| AU2020241693A1 (en) | 2021-09-02 |
| US20220177893A1 (en) | 2022-06-09 |
| JP7564817B2 (ja) | 2024-10-09 |
| SG11202108625WA (en) | 2021-09-29 |
| PE20220168A1 (es) | 2022-01-28 |
| JOP20210254A1 (ar) | 2023-01-30 |
| TW202102675A (zh) | 2021-01-16 |
| CO2021013371A2 (es) | 2021-10-20 |
| BR112021015494A2 (pt) | 2021-10-05 |
| AU2020241693B2 (en) | 2024-01-04 |
| JP2025000805A (ja) | 2025-01-07 |
| JP2022526267A (ja) | 2022-05-24 |
| CN117106778A (zh) | 2023-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002398A1 (es) | Compuestos y métodos para reducir la expresión de kcnt1 | |
| RU2020119390A (ru) | Применение каннабиноидов при лечении приступов, связанных с синдромом леннокса-гасто | |
| ECSP24044340A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| CO2020015256A2 (es) | Compuestos y métodos para la reducción de la expresión de lrrk2 | |
| BR112019007383A2 (pt) | compostos e métodos para reduzir a expressão de atxn3 | |
| BR112015014729A2 (pt) | estrutura côncava, colheitadeira e método de processamento de uma cultura agrícola | |
| RU2020127876A (ru) | Применение каннабиноидов в лечении эпилепсии | |
| UY37967A (es) | Compuestos y métodos para la reducción de la expresión de snca | |
| AR077448A1 (es) | Uno o una combinacion de fito-canabinoides en el tratamiento de epilepsia | |
| WO2011156247A3 (en) | Processor for large graph algorithm computations and matrix operations | |
| ECSP11011026A (es) | Agonistas de los receptores de la melanocortina | |
| CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
| CL2007001228A1 (es) | Uso de una composicion que contiene por lo menos un ciclopropeno para mejorar el rendimiento de una cosecha de una pluralidad de plantas, con la condicion que cuando dichas plantas comprendan manzanos, dicha composicion no contenga aminoetoxivinilgli | |
| CL2021002515A1 (es) | Compuestos y métodos para modular ube3a-ats | |
| MX2020011911A (es) | Compuestos y metodos para reducir de la expresion de atxn3. | |
| MA34020B1 (fr) | Procede de traitement d'infections fongiques compositions fongicides et leur utilisation | |
| CO2022004281A2 (es) | Métodos de tratamiento de la epilepsia utilizando dichos métodos | |
| BR112012013034A2 (pt) | métodos e aparelhos para segregação de partículas, incluindo a segregação e a proliferação de células fetais e células-tronco | |
| CL2024000541A1 (es) | Compuestos y métodos para modular el scn2a | |
| UY39297A (es) | Compuestos y métodos para reducir la expresión de kcnt1 | |
| AR122744A1 (es) | Compuestos y métodos para reducir la expresión de kcnt1 | |
| Armed Forces Health Surveillance Center (AFHSC | Erectile dysfunction among male active component service members, US Armed Forces, 2004-2013 | |
| WO2018039751A3 (en) | Feeder device | |
| CU20160033A7 (es) | Una cinta de alimentación para una cosechadora de caña de azúcar | |
| EA202192527A1 (ru) | Соединения и способы для снижения экспрессии kcnt1 |